Author: Bryan Nordley | August 3, 2026
Question:
How can providers improve the likelihood of coverage or a successful appeal for testing reported with PLA code 0529U?
Answer:
Note that many payer coverage policies assign PLA codes a status of experimental/investigational, which may exclude coverage due to a lack of literature establishing clinical efficacy, safety, or applicability to clinical practice. Alternatively, laboratories may be required to submit documentation from the patient’s medical record to substantiate medical indications and support the medical necessity of testing defined by a PLA code. In the case of 0529U, such documentation might indicate a strong family history or specific high-risk situations, such as planning pregnancy, using estrogen/oral contraceptives, or undergoing major surgery. When seeking prior authorization or appealing a denied claim, it is beneficial to present chart notes supporting the intended use of results in directing treatment decisions, such as guiding anticoagulant duration after a clot or informing hormone use.
This article was originally published on RACmonitor.
